Ricevi le ultime notizie sulle azioni SCYNEXIS con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di SCYX

Ultime notizie per

SCYNEXIS

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

SCYNEXIS Inc

Earnings

Press Releases

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Health Care

SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

News

SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)

SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update

SCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 – 10, 2025

SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)

SCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247)

SCYX

AN2 Therapeutics

Aytu BioPharma

CalciMedica

Cingulate

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical

Cumberland Pharmaceuticals Inc. - Common Stock

Cumberland

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Dare Bioscience

Grace Therapeutics

Hoth Therapeutics

IGC Pharma

Iterum Therapeutics

Incannex Healthcare

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals

ProPhase Labs

PolyPid

Quantum Biopharma Ltd. - Class B Subordinate Voting Shares

Quantum BioPharma

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Hldgs

Rafael Holdings, Inc. Class B Common Stock

Rafael Holdings

Telomir Pharmaceuticals, Inc. - Common Stock

Telomir Pharmaceuticals

Talphera

Traws Pharma

Verrica Pharmaceuticals Inc. - Common Stock

Comments

SCYNEXIS Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO